Biotech Values

[DewDiligence]

Re AMGN/TKTX:

What does this paragraph mean?

http://biz.yahoo.com/prnews/041021/nyth103_1.html
>>
Dynepo, a fully human erythropoietin product produced by TKT's patented gene activation technology, was approved for commercial use in the European Union in 2002 for the treatment of anemia associated with kidney disease. TKT is establishing manufacturing for Dynepo at Lonza's cGMP production facility in Slough, England in a manner consistent with applicable court orders in the U.S. litigation with Amgen and expects to file an amendment to Dynepo's product license in the third quarter of 2005 for the new manufacturing facility.
<<